The Medicines and Healthcare products Regulatory Agency (MHRA) has concluded a blog series reflecting on insights that have shaped its new five-year strategy. Professor Anthony Harnden, MHRA Chair, highlighted key themes including operating as a regulator for all nations of the UK.
The strategy aims to strengthen collaboration with devolved governments and regional partners, ensuring regulatory approaches reflect different contexts while maintaining consistent standards. This includes recognising distinct strengths such as Scotland's clinical research infrastructure and Wales's connected health and care system.
Patient-centred regulation is another core focus, seeking to enable safe innovation, from advanced therapies to AI-enabled technologies, to reach patients more quickly. This involves evolving how evidence is assessed and engaging earlier with innovators.
The MHRA also plans to build a world-class safety and surveillance system. This system will use data more intelligently and link information across sources to identify risks earlier and take targeted action.